CoChat
Sign Up
Cited by 136

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Nanonization techniques to overcome poor water-solubility with drugs

Da Silva, Flávia Lidiane Oliveira, Marques, Maria Betânia De Freitas, Kato, Kelly Cristina, Carneiro, Guilherme·2020·Expert Opinion on Drug Discovery
DOI 10.1080/17460441.2020.1750591
Open this paper in CoChat — free account

Abstract

Introduction Most drugs used in therapy have low water-solubility, a factor that could reduce their dissolution rate and oral bioavailability, representing a challenge in pharmaceutical development. Nanonization of drugs is the reduction of particles to nanoscale, increasing the surface area and consequently the saturation solubility and dissolution rate and resulting in higher bioavailability. Areas covered This review provides an overview of the consequences of the poor water-solubility and the main strategies applied to increase the solubility of poorly water-soluble drugs. The relationship between the biopharmaceutical classification system and the solubilization process of the drug is also considered. Finally, it includes how drug nanoparticles and nanocarriers, especially lipid-based nanosystems, can overcome these challenges and which of these approaches are already available on the market. Expert opinion Due to the growing importance of nanomedicines, especially for applications in poorly water-soluble drugs, it is important to clearly establish the specifications and quality criteria for nanonized drugs to ensure the quality and safety of nanoparticles.

Overview

Integrity signals

Registry

Crossref · 10.1080/17460441.2020.1750591

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 96

  1. Bharti VP, 2015, J Innovations Pharm Biol Sci, 2, 482
  2. 10.7897/2230-8407.0811210 · DOI
  3. 10.5402/2012/195727 · DOI
  4. 10.1021/ja02086a003 · DOI
  5. Kakran M, 2012, Pharm Eng, 32
  6. 10.1021/j100588a008 · DOI
  7. 10.1021/j100549a012 · DOI
  8. Martin A, 2008, Martin: físico-farmácia e ciências farmacêuticas
  9. 10.1208/s12248-008-9036-5 · DOI
  10. Emami J, 2006, J Pharm Pharm Sci, 9, 169
  11. 10.1002/jps.22217 · DOI
  12. 10.1021/mp034006h · DOI
  13. 10.1007/s11095-004-9004-4 · DOI · Paper page
  14. 10.1016/j.ijpharm.2019.05.041 · DOI
  15. 10.1016/j.addr.2012.11.006 · DOI
  16. 10.1080/17460441.2019.1660642 · DOI
  17. 10.1517/17460441.2014.877881 · DOI
  18. 10.1002/bip.1970.360091002 · DOI
  19. 10.1002/9783527652693 · DOI
  20. 10.1021/ja00102a021 · DOI
  21. Langmuir I, 1925, Third Colloid Symp. Monograph
  22. 10.1016/j.jsps.2013.05.004 · DOI
  23. 10.3109/03639045.2014.971027 · DOI
  24. 10.3390/molecules201018759 · DOI
  25. 10.3390/polym11091396 · DOI
  26. Chaudhary VB, 2013, IJPSR, 4, 68
  27. 10.3390/pharmaceutics11030112 · DOI
  28. 10.1016/j.apsb.2013.11.001 · DOI
  29. 10.1016/S0378-5173(01)00867-5 · DOI
  30. 10.1517/17425247.2013.808185 · DOI
  31. 10.2147/DDDT.S103505 · DOI
  32. 10.1517/17425247.2014.881798 · DOI
  33. Lohar V, 2012, Int J Pharm Res, 4, 15
  34. 10.1016/j.addr.2007.05.010 · DOI
  35. 10.3390/pharmaceutics10030108 · DOI
  36. 10.5402/2012/820653 · DOI
  37. Choudhary AN, 2019, Pharma Innovation J, 8, 1149
  38. 10.4314/ijhr.v2i4.55423 · DOI
  39. Kumar VS, 2014, Int J Pharm Pharm Sci, 6, 1
  40. 10.3390/molecules23051161 · DOI
  41. 10.1016/j.ijpharm.2017.04.021 · DOI
  42. Rangel-Yagui CO, 2005, J Pharm Pharm Sci, 8, 147
  43. 10.1208/s12249-008-9057-5 · DOI
  44. Majeed A, 2019, Int J Pharm Sci Res, 10, 1025
  45. 10.1016/j.ajps.2014.05.005 · DOI
  46. European Commission. Second regulatory review on nanomaterials: communication from the commission to the european parliament, the council and the european economic and social committee. Brussels: European Comission; 2012 [cited 2020 Mar 30]. Available at ec.europa.eu/research/industrial_technologies/pdf/policy/communication-from-the-commission-second-regulatory-review-on-nanomaterials_en.pdf
  47. 2014, Food and drug administration. Guidance for industry: considering whether an FDA-regulated product involves the application of nanotechnology
  48. 10.1016/j.jconrel.2009.12.019 · DOI
  49. 10.1016/j.jconrel.2011.09.098 · DOI
  50. 10.1007/978-94-017-8739-0_5 · DOI
  51. 10.1016/j.imlet.2013.11.019 · DOI
  52. 10.1016/j.jconrel.2017.06.003 · DOI
  53. Dizaj SM, 2015, Res Pharm Sci, 10, 95
  54. 10.1016/j.bbrc.2019.09.004 · DOI
  55. 10.3390/molecules25020338 · DOI
  56. 10.4155/tde-2017-0090 · DOI
  57. 10.1002/jbm.b.34426 · DOI
  58. 10.1208/s12249-019-1597-3 · DOI
  59. 10.1016/j.msec.2019.03.002 · DOI
  60. 10.1016/j.ijbiomac.2019.01.142 · DOI
  61. 10.1016/j.foodchem.2019.125328 · DOI
  62. 10.1002/cbin.10459 · DOI
  63. 10.1016/j.drudis.2018.01.016 · DOI
  64. 10.2174/1381612824666180515154109 · DOI
  65. 10.1016/j.ijpharm.2017.10.046 · DOI
  66. 10.3109/08982104.2013.819888 · DOI
  67. 10.3389/fphar.2015.00286 · DOI
  68. Hua S, 2013, Front Pharmacol, 21, 143
  69. 10.1002/jps.2600821102 · DOI
  70. 10.1016/j.cocis.2005.06.004 · DOI
  71. Singhal GB, 2011, Int Res J Pharm, 2, 40
  72. 10.2174/092986712803251584 · DOI
  73. 10.1016/j.biopha.2004.02.001 · DOI
  74. 10.1080/17425247.2016.1218462 · DOI
  75. 10.3109/03639045.2012.660949 · DOI
  76. Wadhwa J, 2012, Acta Poloniae Pharm Drug Res, 69, 179
  77. 10.1208/s12249-019-1335-x · DOI
  78. 10.3109/1061186X.2014.934688 · DOI
  79. 10.1080/10611860701538586 · DOI
  80. 10.1517/17425240903436479 · DOI
  81. 10.2174/187221111797200597 · DOI
  82. 10.1016/j.ejps.2012.05.010 · DOI
  83. 10.1016/S0169-409X(02)00118-7 · DOI
  84. 10.1016/j.nano.2015.09.004 · DOI
  85. 10.1016/j.addr.2003.12.002 · DOI
  86. 10.1016/j.ijpharm.2013.12.006 · DOI
  87. 10.1517/17425247.2012.673278 · DOI
  88. 10.1016/j.plipres.2017.07.001 · DOI
  89. 10.2147/DDDT.S99651 · DOI
  90. 10.1080/1061186X.2018.1512112 · DOI
  91. 10.1080/17425247.2016.1193149 · DOI
  92. 10.3109/10717544.2015.1048488 · DOI
  93. 10.3390/molecules25020332 · DOI
  94. 10.1155/2019/2834941 · DOI
  95. 10.1007/s40005-017-0370-4 · DOI
  96. 10.2217/nnm-2018-0120 · DOI

Cited by

Sorted by citations

Metadata

Authors
Da Silva, F. L. O., Marques, M. B. D. F., Kato, K. C., & Carneiro, G.
Venue
Expert Opinion on Drug Discovery
Publisher
Informa UK Limited
Published
2020-04-15
Volume
15
Issue
7
Pages
853-864
ISSN
  • 1746-0441
  • 1746-045X
DOI
10.1080/17460441.2020.1750591
Cited by
136
References
4
Language
en
Funders
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review